Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non-Small Cell Lung Cancer
Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non-Small Cell Lung Cancer
复制标题
DOI：
10.1148/radiol.12111148
复制
发表时间：
2012-08-01
期刊：
影响因子：
19.7
通讯作者：
Lee, Bi-Fang
中科院分区：
文献类型：
--
作者：
Chen, Helen H. W.;Chiu, Nan-Tsing;Lee, Bi-Fang
目的：确定全身总病灶糖酵解（TLG）结合了氟18氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）的体积和代谢信息，是否可以更好地评估非小细胞肺癌（NSCLC）的预后。 材料和方法：机构审查委员会批准了这项回顾性研究，并免除了获得知情同意的要求。作者确定了 105 名连续 NSCLC 患者，他们在任何治疗前均接受了 FDG PET/CT 分期。这些患者没有脑转移，并接受了标准治疗和随后的临床随访。测定全身每个肿瘤的代谢肿瘤体积（MTV）、平均标准化摄取值（SUV）和最大SUV。全身 MTV 和全身 TLG 分别是所有 MTV 的总和以及单个肿瘤体积乘以其平均 SUV 的总和。通过单变量和多变量分析评估全身TLG和其他因素的预后意义，包括全身MTV、肺TLG、肺MTV、最大SUV、性别、年龄、体能状态、组织学亚型、T分期、N分期、临床分期和治疗方法。结果：中位随访时间为3.1年。该队列的估计中位无进展生存期 (PFS) 和总生存期 (OS) 分别为 10.8 个月和 2.8 年。全身 TLG 高 (>655) 的患者的 1 年 PFS 为 0.0%，全身 TLG 低的患者为 50.0%（
Purpose: To determine whether whole-body total lesion glycolysis (TLG), which combines volumetric and metabolic information from fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), can provide a better evaluation of the prognosis for non-small cell lung cancer (NSCLC).Materials and Methods: The institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived. The authors identified 105 consecutive patients with NSCLC who underwent staging FDG PET/CT before any therapy. These patients were free of brain metastasis and underwent standard treatment and subsequent clinical follow-up. Metabolic tumor volume (MTV), mean standardized uptake value (SUV), and maximum SUV of each tumor over the whole body were determined. Whole-body MTV and whole-body TLG are the summation of all the MTVs and summation of individual tumor volume multiplied by its mean SUV, respectively. Univariate and multivariate analyses were performed to assess the prognostic significance of whole-body TLG and other factors, including whole-body MTV, lung TLG, lung MTV, maximum SUV, sex, age, performance status, histologic subtype, T stage, N stage, clinical stage, and treatment method.Results: The median follow-up time was 3.1 years. The estimated median progression-free survival (PFS) and overall survival (OS) for the cohort was 10.8 months and 2.8 years, respectively. The 1-year PFS was 0.0% for patients with high whole-body TLG (>655) and 50.0% for those with low whole-body TLG (